Product Name :
GSK2879552, LSD1 Inhibitor
Description:
GSK2879552 is a highly potent, selective and orally bioavailable irreversible inhibitor of Lysine Specific Demethylase 1 (LSD1). It is highly selective over related enzymes such as MAO-A/B. A proliferation screen of cell lines representing a number of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to GSK2879552’s inhibition. It increases H3K4 methylation selectively at genomic regions bound by LSD1. It demonstrates efficacy in preclinical models of SCLC. Currently GSK2879552 is in phase I clinical trials targeting Acute Myeloid Leukemia (AML) and Relapsed/Refractory Small Cell Lung Carcinoma.
CAS:
1902123-72-1
Molecular Weight:
437.40
Formula:
C23H30Cl2N2O2
Chemical Name:
4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid hydrochloride
Smiles :
Cl.Cl.OC(=O)C1=CC=C(CN2CCC(CN[C@@H]3C[C@H]3C3C=CC=CC=3)CC2)C=C1
InChiKey:
QEKGSBZKRLHQSZ-VSIGASKDSA-N
InChi :
InChI=1S/C23H28N2O2.2ClH/c26-23(27)20-8-6-18(7-9-20)16-25-12-10-17(11-13-25)15-24-22-14-21(22)19-4-2-1-3-5-19;;/h1-9,17,21-22,24H,10-16H2,(H,26,27);2*1H/t21-,22+;;/m0../s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Daclizumab} medchemexpress|{Daclizumab} Interleukin Related|{Daclizumab} Protocol|{Daclizumab} Data Sheet|{Daclizumab} supplier|{Daclizumab} Autophagy}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
GSK2879552 is a highly potent, selective and orally bioavailable irreversible inhibitor of Lysine Specific Demethylase 1 (LSD1). It is highly selective over related enzymes such as MAO-A/B. A proliferation screen of cell lines representing a number of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to GSK2879552’s inhibition. It increases H3K4 methylation selectively at genomic regions bound by LSD1. It demonstrates efficacy in preclinical models of SCLC. Currently GSK2879552 is in phase I clinical trials targeting Acute Myeloid Leukemia (AML) and Relapsed/Refractory Small Cell Lung Carcinoma.{{Recombinant Murine Interleukin-6} MedChemExpress|{Recombinant Murine Interleukin-6} Biological Activity|{Recombinant Murine Interleukin-6} Purity|{Recombinant Murine Interleukin-6} manufacturer|{Recombinant Murine Interleukin-6} Cancer} |Product information|CAS Number: 1902123-72-1|Molecular Weight: 437.PMID:24624203 40|Formula: C23H30Cl2N2O2|Related CAS Number:|1401966-69-5 (free base)|2002466-63-7 (2 HCl+4H2O)|1401966-63-9 (meso)|2121592-35-4 (meso, HCl)|Chemical Name: 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid hydrochloride|Smiles: Cl.Cl.OC(=O)C1=CC=C(CN2CCC(CN[C@@H]3C[C@H]3C3C=CC=CC=3)CC2)C=C1|InChiKey: QEKGSBZKRLHQSZ-VSIGASKDSA-N|InChi: InChI=1S/C23H28N2O2.2ClH/c26-23(27)20-8-6-18(7-9-20)16-25-12-10-17(11-13-25)15-24-22-14-21(22)19-4-2-1-3-5-19;;/h1-9,17,21-22,24H,10-16H2,(H,26,27);2*1H/t21-,22+;;/m0../s1|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO up to 50 mM; Water up to 50 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|GSK2879552 was used at 1 µM in vitro and cellular assays.|In Vivo:|GSK2879552 was orally dosed to mice at 1.5-10 mg/Kg once per day.|References:|Mohammad HP, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. (2015) Cancer Cell. 28(1):57-69.Maes T, et al. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. (2015) Epigenomics. 7(4):609-26.Products are for research use only. Not for human use.|Documents||
